This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
30 Jul 2025

https://www.linkedin.com/posts/kunal-saxena2023_rusanpharma-rpci-freedomfromdependence-activity-7344632244029853696-PD_f?utm_source=share&utm_medium=member_desktop&rcm=ACoAAD4lXHUB53BArnSboqfyXl_xXGnCi-M9cLQ

We are happy to announce the approval of our first finished dosage formulation (FDF) in Canada - RPC-Naltrexone Film-Coated Tablets (50 mg) (DIN: 02558343), through our subsidiary Rusan Pharma Canada Inc (RPCI).Rusan's Active Pharmaceutical Ingredient (API) and FDF manufacturing facilities are Health Canada GMP approved. With our integration to in-house manufacturing of the API - Naltrexone Hydrochloride, we plan to ensure that product has a robust supply chain and has a pan-Canadian reach.With this approval, we are excited to launch Rusan's global initiative and mission "FREEDOM FROM DEPENDENCE (PROJECT FREEDENCE)". Under this mission, we plan to become a global leader in addiction care (drugs, alcohol and tobacco), by introducing globally accepted treament standards such as Naltrexone Tablets, Buprenorphine+Naloxone Sublingual Tablets and films, Methadone Oral Solution, Nicotine gums, oral films and transdermal patches and other innovative delivery solutions.I am excited th...

We are happy to announce the approval of our first finished dosage formulation (FDF) in Canada - RPC-Naltrexone Film-Coated Tablets (50 mg) (DIN: 02558343), through our subsidiary Rusan Pharma Canada Inc (RPCI).Rusan's Active Pharmaceutical Ingredient (API) and FDF manufacturing facilities are Health Canada GMP approved. With our integration to in-house manufacturing of the API - Naltrexone Hydrochloride, we plan to ensure that product has a robust supply chain and has a pan-Canadian reach.With this approval, we are excited to launch Rusan's global initiative and mission "FREEDOM FROM DEPENDENCE (PROJECT FREEDENCE)". Under this mission, we plan to become a global leader in addiction care (drugs, alcohol and tobacco), by introducing globally accepted treament standards such as Naltrexone Tablets, Buprenorphine+Naloxone Sublingual Tablets and films, Methadone Oral Solution, Nicotine gums, oral films and transdermal patches and other innovative delivery solutions.I am excited th...

Mentioned Companies
Rusan Pharma Ltd
View company profile